| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Lantus Articles
The study showed that people with type 2 treated with Lantus and Apidra achieved significant reductions in their A1c compared to those treated with pre-mixed insulin.
This press release is an announcement submitted by Sanofi-aventis, and was not written by Diabetes Health.
At the recent 44th annual meeting of the European Association for the Study of Diabetes (EASD), sanofi-aventis announced a study demonstrating that a basal-bolus insulin regimen with Lantus® once daily (basal insulin) and rapid-acting Apidra® (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) resulted in significant A1c reductions from baseline as compared to pre-mixed insulin in people with type 2 diabetes.
In the GINGER study, the overall A1c change from baseline to endpoint with Lantus and Apidra was 1.3% versus 0.8% with pre-mix. The number of patients who reached an A1c of less than 7.0% at endpoint was significantly higher with Lantus and Apidra when compared to pre-mixed insulin.
Source: Sanofi-aventis
Categories: A1c Test, Apidra, Insulin, Lantus, Type 2 Issues, Type 2 Medications
4 comments -
Sep 29, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.